Phase 4
Completed N=100
Dexamethasone vs Ondansetron After Cesarean Delivery
Nausea and Vomiting, Postoperative · Cesarean Section Complications
Source: ClinicalTrials.gov NCT05692245 ↗
Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcomePrimary: Medications Received — 0.23; 0.40 Medications
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The goal of this clinical trial is to compare medications in women having a cesarean delivery. The main question it aims to answer are:
• Which medication is better to use as a first-line prevention agent for nausea and vomiting Participants will rate their nausea, pain and other symptoms after surgery Researchers will compare two drugs, ondansetron and dexamethasone to see if the side effects of pain medications are improved after cesarean.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Medications Received |
0.23; 0.40 | — |
| SECONDARY Severity of Nausea |
0; 0 | — |
| SECONDARY Severity of Pain |
3; 2.7 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy women (ASA 2)
- Between 18 and 45 years old
- Singleton term pregnancies
- Scheduled or non-labor cesarean delivery
- Neuraxial (spinal or combined-spinal epidural) anesthesia
Exclusion Criteria
- Refusal to participate
- Known allergy or contraindication to any medication used in the study
- Significant medical or obstetrical disease (ASA ≥ 3)
- Antiemetic use within 24 hours preceding cesarean delivery
- Insulin dependent diabetes
- Hyperemesis gravidarum or chronic antiemetic use
- History of daily or near-daily steroid use during pregnancy
- Opioid use disorder or other chronic pain syndrome
- Opioid use during pregnancy
- Use of antipruritus medication, pruritic urticarial papules of pregnancy, or cholestasis of pregnancy
Data sourced from ClinicalTrials.gov (NCT05692245). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.